Targinta AB
559157-6698ActiveDeveloping targeted antibodies and ADCs for aggressive cancers.
Biotechnology Company / Pharmaceutical Development Subsidiarytarginta.se
Yleiskatsaus
- 0
- Työntekijät
- ≤1t SEK
- Liikevaihto
- 2018
- Perustettu
Avainpäättäjät
Evy Lundgren-Åkerlund
CSO
@targinta.se
Kuvaus
Targinta AB is a Swedish biotechnology company focused on developing novel treatments for aggressive and life-threatening cancers. The company specializes in creating targeted, toxin-armed antibodies, known as Antibody-Drug Conjugates (ADCs), and functional blocking antibodies. Their entire product...
Tunnisteet
B2B